GUTS Fractyl Health, Inc. Common Stock Loading... : Investor Sentiment and Bull/Bear Views
Loading chart...
Top Calls
No data yet
Price change since each call, adjusted for long/short direction. Results calculated:
Feed
06:15
Jan 20
Jan 20
Short GUTS on gene therapy execution risk — transduction variability across cell lines, genes.
Short GUTS on gene therapy execution risk — transduction variability across cell lines, genes, health status, injection sites, and AAV neutralizing antibodies creates unpredictable dosing outcomes; β-cell longevity means adverse effects (perma-nausea) could be permanent, driving patients toward alternatives and undermining commercial viability.
MED
11:08
Jan 08
Jan 08
Bullish Fractyl Health on Revita GLP-1 maintenance, 2026 catalysts
Author is long-biased on Fractyl Health ($GUTS), a biotech whose Revita one-off procedure may let patients stopping GLP-1s such as Mounjaro or Wegovy maintain weight loss. The mechanism is a large obesity/weight-loss market and a simple procedure that could appeal to patients, practitioners, insurers and regulators, especially after an Oxford study cited by the author said stopping GLP-1s leads to weight regain. Catalysts include 6-month randomized data at the end of January and seven back-to-back 2026 events culminating in an FDA premarket approval filing; the author also notes cash runway into early 2027 and a new CFO hire.
HIGH
About GUTS Investor Commentary
Across the available history and selected sources, Buzzberg tracks GUTS (Fractyl Health, Inc. Common Stock) across 3 sources: 1 bullish vs 1 bearish calls from 3 authors. Historical directional balance: 0% = 100 × (bullish − bearish) / all deduplicated idea records, including other directions. This is neither a probability of a price rise nor the share of bullish authors. 3 total trade ideas tracked. Latest voices: A May MD, Grant Beaty, u/fousekis7.